Johnson & Johnson has reported low incidence rates of treatment-related events with the combination of Rybrevant and Lazartinib under preventive supportive therapy at WCLC 2026.

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.

Taiho and Cullinan's zipalertinib hits its Phase 3 goal in lung cancer, setting up a fight with J&J's Rybrevant.

• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across aty...

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer

Johnson & Johnson has received coal in its stocking from the FDA as manufacturing issues have tripped up the company’s attempt to gain approval of its subcutaneous version of lung cancer drug R | The ...

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

The FDA cited issues with a manufacturing facility as the reason for the rejection. J&J is currently “working closely” with the regulator to resolve these problems.

Official answer: Rybrevant is a targeted medicine that works at the epidermal growth factor receptor (EGFR) gene mutation and MET...

(CercleFinance.com) - Johnson & Johnson annonce que la FDA des Etats-Unis a approuvé Rybrevant associé à Lazcluze pour le traitement de première ligne des adultes atteints d'un cancer du poumon non à ...

Positive opinion issued for marketing authorisation extension

FDA has approved RYBREVANT FASPRO™/ subcutaneous amivantamab with lazertinib as the first and only subcutaneous therapy available across all approved indications for EGFR-mutated NSCLC. 🧬 This approva...

FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are […]

• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across aty...

Otros informes son de Fasenra, para ranulomatosis con poliangeitis; Filspari, para nefropatía por inmunoglobulina A primaria; y Veoza, para menopausia.

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.